Nebenwirkungen · MabThera
MabThera 1600 mg solution for subcutaneous injection · Abschnitt 4.8 · PDF-Seite 89
HOS-087737 · Präparat HOS-083527
Table 1 Adverse reactions reported in clinical trials or during post-marketing surveillance in patients with NHL and CLL disease treated with MabThera monotherapy/maintenance or in combination with chemotherapy MedDRA Very System Organ Common Uncommon Rare Very Rare Not known Common Class Infections and bacterial sepsis, serious viral progressive multifocal enteroviral infestations infections, +pneumonia, infection2, leukoencephalopathy meningoenceph viral +febrile infection, pneumocystis alitis2, 3 infections, +herpes zoster, jirovecii +bronchitis +respiratory tract pneumonia infection, fungal infections, infections of unknown aetiology, +acute bronchitis, +sinusitis,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T15:15:00Z · SHA-256 595c4e1a263e9a34be8b62842a5fc67f95f6a1b1f2a250341444a2960c6c3962 · Passage da5462ba623df9c81a663efdf70afeb85f6c49b30d173f3296541bd642bfb271 · Zeichen 4801–6150 im Abschnitt